WEBSITE BSE:544122 NSE: ENTERO Inc. Year: 2018 Industry: Trading
Last updated: 15:53
Entero Healthcare Solutions Limited (NSE:ENTERO) is a medical technology company based in India that develops and manufactures medical devices and disposables. Entero was founded in 2007 and is headquartered in New Delhi. Entero Healthcare operates manufacturing facilities in Manesar, Haryana and has over 500 employees. It focuses on single-use disposable medical devices used in critical care, anesthesia, surgery, dialysis, infusion therapy, obstetrics and gynecology.Entero Healthcare has a strong domestic market presence in India and exports i...Read More
Entero Healthcare Solutions Limited (NSE:ENTERO) is a medical technology company based in India that develops and manufactures medical devices and disposables. Entero was founded in 2007 and is headquartered in New Delhi. Entero Healthcare operates manufacturing facilities in Manesar, Haryana and has over 500 employees. It focuses on single-use disposable medical devices used in critical care, anesthesia, surgery, dialysis, infusion therapy, obstetrics and gynecology.Entero Healthcare has a strong domestic market presence in India and exports its products to over 30 countries globally. The company is ISO 13485 certified for its quality management system. Entero aims to provide high quality yet affordable medical devices to help improve healthcare access. It is privately held and has received funding from investors such as Sequoia Capital. Entero states its vision is to become a globally trusted medical devices supplier through patient-centric innovation and customization of products for local markets ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹4963 Cr.
Stock P/E 46.2
P/B 2.8
Current Price ₹1140.7
Book Value ₹ 405.9
Face Value 10
52W High ₹1509.9
Dividend Yield 0%
52W Low ₹ 944
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 899 | 996 | 993 | 1034 | 1097 | 1301 | 1359 | 1339 | 1404 | 1571 |
| Other Income | 1 | 2 | 2 | 9 | 13 | 11 | 7 | 7 | 6 | 5 |
| Total Income | 901 | 998 | 994 | 1043 | 1110 | 1312 | 1366 | 1346 | 1410 | 1576 |
| Total Expenditure | 873 | 968 | 964 | 1005 | 1067 | 1258 | 1309 | 1290 | 1354 | 1509 |
| Operating Profit | 27 | 31 | 30 | 38 | 44 | 54 | 58 | 56 | 56 | 67 |
| Interest | 14 | 18 | 16 | 17 | 10 | 11 | 10 | 10 | 11 | 12 |
| Depreciation | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 | 10 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 7 | 7 | 8 | 14 | 27 | 35 | 39 | 37 | 36 | 45 |
| Provision for Tax | 0 | 2 | 1 | -8 | 7 | 9 | 10 | 6 | 6 | 8 |
| Profit After Tax | 6 | 5 | 7 | 21 | 21 | 26 | 29 | 31 | 30 | 37 |
| Adjustments | -0 | -0 | -0 | -0 | -0 | -2 | -4 | -6 | -2 | -5 |
| Profit After Adjustments | 6 | 5 | 7 | 21 | 20 | 24 | 25 | 26 | 28 | 32 |
| Adjusted Earnings Per Share | 15.2 | 3.2 | 4.2 | 4.8 | 4.6 | 5.4 | 5.8 | 5.9 | 6.4 | 7.3 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 1780 | 2522 | 3300 | 3922 | 5096 | 5673 |
| Other Income | 4 | 4 | 6 | 14 | 40 | 25 |
| Total Income | 1784 | 2527 | 3306 | 3937 | 5135 | 5698 |
| Total Expenditure | 1758 | 2498 | 3236 | 3810 | 4924 | 5462 |
| Operating Profit | 25 | 29 | 70 | 126 | 211 | 237 |
| Interest | 20 | 29 | 49 | 66 | 42 | 43 |
| Depreciation | 16 | 20 | 24 | 25 | 31 | 35 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -11 | -20 | -4 | 36 | 139 | 157 |
| Provision for Tax | 5 | 10 | 7 | -4 | 31 | 30 |
| Profit After Tax | -15 | -29 | -11 | 40 | 107 | 127 |
| Adjustments | -0 | -0 | -0 | -1 | -13 | -17 |
| Profit After Adjustments | -16 | -30 | -12 | 39 | 95 | 111 |
| Adjusted Earnings Per Share | -1553.7 | -77.7 | -28.1 | 9 | 21.8 | 25.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 30% | 26% | 0% | 0% |
| Operating Profit CAGR | 67% | 94% | 0% | 0% |
| PAT CAGR | 168% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -23% | NA% | NA% | NA% |
| ROE Average | 6% | 4% | 2% | 2% |
| ROCE Average | 9% | 7% | 5% | 5% |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Shareholder's Funds | 485 | 561 | 595 | 1638 | 1724 |
| Minority's Interest | 2 | 2 | 3 | 3 | 46 |
| Borrowings | 0 | 37 | 31 | 46 | 0 |
| Other Non-Current Liabilities | 57 | 63 | 54 | 37 | 73 |
| Total Current Liabilities | 289 | 462 | 624 | 602 | 845 |
| Total Liabilities | 833 | 1125 | 1307 | 2326 | 2688 |
| Fixed Assets | 189 | 262 | 268 | 289 | 559 |
| Other Non-Current Assets | 12 | 12 | 16 | 26 | 53 |
| Total Current Assets | 633 | 851 | 1023 | 2011 | 2076 |
| Total Assets | 833 | 1125 | 1307 | 2326 | 2688 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 43 | 32 | 47 | 25 | 148 |
| Cash Flow from Operating Activities | -69 | -35 | -45 | -37 | -77 |
| Cash Flow from Investing Activities | -31 | -162 | -49 | -705 | 220 |
| Cash Flow from Financing Activities | 89 | 211 | 73 | 863 | -74 |
| Net Cash Inflow / Outflow | -11 | 14 | -21 | 121 | 69 |
| Closing Cash & Cash Equivalent | 32 | 47 | 25 | 148 | 229 |
| # | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -1553.7 | -77.71 | -28.11 | 8.99 | 21.79 |
| CEPS(Rs) | 92.2 | -25.16 | 31.94 | 14.9 | 31.75 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | -3174.6 | -150.52 | -166.8 | 376.21 | 395.31 |
| Core EBITDA Margin(%) | 1.21 | 0.97 | 1.94 | 2.85 | 3.37 |
| EBIT Margin(%) | 0.52 | 0.36 | 1.37 | 2.58 | 3.54 |
| Pre Tax Margin(%) | -0.61 | -0.79 | -0.11 | 0.91 | 2.72 |
| PAT Margin (%) | -0.86 | -1.17 | -0.34 | 1.01 | 2.11 |
| Cash Profit Margin (%) | 0.05 | -0.38 | 0.4 | 1.65 | 2.71 |
| ROA(%) | -1.84 | -3.01 | -0.91 | 2.19 | 4.29 |
| ROE(%) | 0 | 0 | 0 | 5.08 | 6.4 |
| ROCE(%) | 1.47 | 1.24 | 4.99 | 7.02 | 9.16 |
| Receivable days | 49.66 | 44.63 | 49.19 | 52.59 | 51.78 |
| Inventory Days | 50.03 | 40.09 | 36.04 | 35.49 | 38.71 |
| Payable days | 21.55 | 18.67 | 21.08 | 22.51 | 24.83 |
| PER(x) | 0 | 0 | 0 | 109.53 | 52.15 |
| Price/Book(x) | 0 | 0 | 0 | 2.62 | 2.88 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.32 | 0.32 | 0.28 | 0.93 | 0.98 |
| EV/Core EBITDA(x) | 22.61 | 27.75 | 13.45 | 29.04 | 23.61 |
| Net Sales Growth(%) | 0 | 41.71 | 30.85 | 18.85 | 29.92 |
| EBIT Growth(%) | 0 | -0.36 | 393.99 | 123.56 | 78.15 |
| PAT Growth(%) | 0 | -91.74 | 62.28 | 458.42 | 169.94 |
| EPS Growth(%) | 0 | 95 | 63.83 | 131.99 | 142.37 |
| Debt/Equity(x) | 0.29 | 0.51 | 0.63 | 0.17 | 0.17 |
| Current Ratio(x) | 2.19 | 1.84 | 1.64 | 3.34 | 2.46 |
| Quick Ratio(x) | 1.35 | 1.17 | 1.09 | 2.64 | 1.68 |
| Interest Cover(x) | 0.46 | 0.32 | 0.92 | 1.54 | 4.33 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.06 | 0.06 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Promoter | 52.44 | 52.44 | 52.44 | 52.44 | 52.42 | 52.42 | 52.42 | 52.42 |
| FII | 23.3 | 23.32 | 23.82 | 22.21 | 19.92 | 17.2 | 14.67 | 5.14 |
| DII | 2.28 | 2.06 | 7.73 | 8.77 | 9.64 | 10.18 | 9.65 | 16.42 |
| Public | 21.99 | 22.18 | 16.01 | 16.59 | 18.02 | 20.19 | 23.26 | 26.02 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Promoter | 2.28 | 2.28 | 2.28 | 2.28 | 2.28 | 2.28 | 2.28 | 2.28 |
| FII | 1.01 | 1.01 | 1.04 | 0.97 | 0.87 | 0.75 | 0.64 | 0.22 |
| DII | 0.1 | 0.09 | 0.34 | 0.38 | 0.42 | 0.44 | 0.42 | 0.71 |
| Public | 0.96 | 0.96 | 0.7 | 0.72 | 0.78 | 0.88 | 1.01 | 1.13 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4.35 | 4.35 | 4.35 | 4.35 | 4.35 | 4.35 | 4.35 | 4.35 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
